Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary cancer prevention trials.

E T Hawk1, S M Lippman

  • 1Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.

Hematology/Oncology Clinics of North America
|August 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunological and classical subtypes of oral premalignant lesions.

Oncoimmunology·2018
Same author

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Leukemia & lymphoma·2016
Same author

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Prostate cancer and prostatic diseases·2015
Same author

Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2014
Same author

The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Cancer prevention research can learn from cardiovascular disease prevention successes. Implementing effective cancer prevention strategies requires addressing access to care and promoting healthy lifestyles for all populations.

Area of Science:

  • Oncology
  • Cardiovascular Disease Prevention
  • Public Health

Background:

  • Cardiovascular disease prevention has seen significant clinical impact over 50 years, with major declines in mortality.
  • Improvements in treatment and secondary prevention, alongside primary prevention, drove these trends.
  • Cancer chemoprevention has progressed but can benefit from cardiovascular disease prevention strategies.

Purpose of the Study:

  • To highlight lessons from cardiovascular disease prevention for cancer chemoprevention.
  • To emphasize the need for accessible and utilized preventive services.
  • To advocate for integrated approaches combining drug therapy and lifestyle interventions.

Main Methods:

  • Review of historical trends in cardiovascular disease mortality.

Related Experiment Videos

  • Analysis of factors contributing to cardiovascular disease risk reduction.
  • Conceptual framework for applying prevention models to cancer.

    • Main Results:

    • Cardiovascular disease mortality declined substantially due to primary and secondary prevention efforts.
    • Primary prevention's impact was noted before widespread drug availability, suggesting broader lifestyle influences.
    • Late-stage cancer diagnosis is more prevalent in uninsured and Medicaid populations, indicating disparities in access.

    Conclusions:

    • Cancer prevention can achieve clinical reality by adopting strategies from cardiovascular disease prevention.
    • Effective cancer prevention requires overcoming barriers to service utilization and addressing socioeconomic disparities.
    • Optimal cancer prevention likely involves a combination of targeted drug therapies and public health initiatives promoting healthy lifestyles.